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The chemical mixture of disinfection by-
products (DBPs) has not been fully character-
ized but is known to contain trihalomethanes
(THMs), haloacetic acids (HAAs), haloace-
tonitriles, and other classes of chemicals, some
of which are mutagenic or carcinogenic in
laboratory animals (Nieuwenhuijsen et al.
2000). Total THMs (TTHMs) are the sum of
the concentrations of the THM species chloro-
form, bromodichloromethane (BDCM),
dibromochloromethane (DBCM), and bro-
moform. The five regulated HAAs (HAA5)
include monochloroacetic acid (MCAA),
dichloroacetic acid (DCAA), trichloroacetic
acid (TCAA), monobromoacetic acid (MBAA),
and dibromoacetic acid (DBAA). Concerns
have been raised regarding the potential effects
of by-products on reproductive outcomes,
supported in part by the findings that some
by-products cause reproductive and develop-
mental toxicity in laboratory animals, albeit
at doses much higher than those encountered
by humans. In addition, exposure to DBPs
has been associated with an increased risk of
impaired fetal growth in several epidemiologic
studies (Bove et al. 1995; Dodds et al. 1999;
Gallagher et al. 1998; Kramer et al. 1992;
Savitz et al. 1995; Wright et al. 2003).
The third trimester of pregnancy is consid-
ered the period of human fetal development
during which fetal growth and birth weight are
maximally sensitive to environmental influ-
ences (Kline et al. 1989). The third trimester
lasts from approximately the 26th week of ges-
tation to parturition, with the actual length of
time dependent on the individual pregnancy.
However, only a few prior investigations of
DBPs have evaluated exposure during this
period (Dodds et al. 1999; Gallagher et al.
1998; Savitz et al. 1995; Wright et al. 2003).
Risks for adverse birth outcomes depend on
the magnitude of exposure over critical time
windows. Therefore, analyses over exposure
windows that are too wide may bias risk esti-
mates. Because the critical time period for the
potential effects of DBP exposure on fetal
growth is uncertain, the use of multiple,
shorter exposure windows may provide less
biased risk estimates (Hertz-Picciotto et al.
1996). The purpose of this study was to exam-
ine the effects of exposure to THMs and
HAAs during the third trimester and during
individual weeks and months of late gestation
on the risks for term low birth weight,
intrauterine growth retardation, and very
preterm and preterm births.
Materials and Methods
We conducted a retrospective cohort study in a
large Arizona community served by three water
treatment facilities. This community of more
than half a million residents living in 24 ZIP
codes is located adjacent to a major metropoli-
tan area. Most water used by this community
originates from surface water sources by means
of the Salt River and Central Arizona projects.
The community was selected from the
U.S. Environmental Protection Agency
(EPA) Information Collection Rule database
(U.S. EPA 1999) because the distribution sys-
tems displayed large temporal fluctuations
(range, 7–81 µg/L) and low spatial variability
in TTHM levels that permitted a natural
experiment through intracommunity com-
parisons of exposures and outcomes. We
determined spatial variability using the meth-
ods described by Hinckley et al. (2005).
Briefly, we classified a facility as having low
spatial variability if TTHM values measured
at four points in the facility’s distribution sys-
tem consistently fell, each season, within
established boundaries for low, medium, and
high exposure as based on concentration cut-
points for TTHMs derived from prior epi-
demiologic studies of birth outcomes. The
study population included all live births and
fetal deaths for women whose residence was
provided water by one of three facilities serving
the community from January 1998 through
December 2002. Table 1 summarizes the
annual frequency of births in this population,
as well as the distribution of TTHM and
HAA5 concentrations by year over the period
of the study. This study was approved by the
human subjects institutional review boards of
Colorado State University and the Arizona
Department of Health Services.
Subjects were identiﬁed from Arizona birth
records (n = 48,119) and were matched to a
facility service area by residential ZIP code. In
cases where two facilities shared the same dis-
tribution system, treatment facility employees
identified service boundaries. Subjects who
lived in ZIP codes that received water from
more than one facility were excluded from
the analysis. Maternal residence at birth was
assumed to be the same as residence during the
third trimester.
We estimated exposure from data obtained
from each facility (facilities A–C) for the years
1998–2002. Total and individual THMs were
measured quarterly during each of the 5 years,
for each of the facilities. Facility A provided
quarterly THM and HAA data for the entire
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2001 and 2002. At facilities B and C, HAA5
data were available only for 2000 and 2002.
Supplemental monthly and biweekly TTHM
and HAA5 data were provided by facility B
for 2000 and 2002, respectively. DBP con-
centrations were monitored at two to four
locations within the distribution system of
each facility. The quarterly and monthly data
indicated the presence of very low levels of
bromoform, MBAA, and MCAA; therefore,
these chemicals were not included in the
analyses. To estimate DBP values for speciﬁc
study periods corresponding to months when
no data were available, we performed a spline
regression (Greenland 1998) for each water
facility to impute the missing values using pro-
cedures similar to those used by investigators in
Nova Scotia (Dodds et al. 1999; Dodds and
King 2001; King et al. 2000). This nonlinear
smoothing technique was applied to impute
missing exposure data from existing data by
generating a joined series of parabolic curve seg-
ments. HAA exposure data were not estimated
before the year 2000 for facilities B and C.
Infant outcomes were identified through
vital records. The date of last menstrual period
was used to deﬁne the duration of gestation.
We identiﬁed infants born at ≥ 37 completed
weeks of gestation and weighing < 2,500 g as
being term low birth weight. We evaluated this
outcome only among term births to separate
children with true growth retardation from
babies that are small because of birth at a
young gestational age. We identified case
infants with intrauterine growth retardation as
term or preterm babies that fell below the pub-
lished value for the lowest 10th percentile of
birth weights by race, ethnicity, and gestation
age (Alexander et al. 1999). In this investiga-
tion, term low birth weight and intrauterine
growth retardation were not mutually exclu-
sive, and cases born at term may have been
included in both outcome groups. Because
published values for the lowest 10th percentile
of birth weights were not available for extreme
gestational ages, births before 23 weeks’ gesta-
tion were excluded from intrauterine growth
retardation analyses for Caucasians, African
Americans, and Hispanics, and births before
29 weeks’ gestation were excluded for Native
Americans (Alexander et al. 1999). For intra-
uterine growth retardation and term low birth
weight, estimated monthly DBP exposures were
averaged over the third trimester. Additionally,
for DBPs associated with intrauterine growth
retardation or term low birth weight, we aver-
aged and evaluated exposure during specific
time windows, corresponding to gestation weeks
25–28, 29–32, 33–36, 37–40, and 41–44,
using monthly DBP concentrations.
Preterm births were defined as infants
born at < 37 completed weeks of gestation.
Very preterm births were defined as a birth
occurring before 32 completed weeks of ges-
tation (Martin et al. 2002). Because preterm
birth outcomes are deﬁned by time length of
gestation, it was inappropriate to evaluate
exposure averaged over the third trimester.
Preterm births have shorter gestation lengths
than the typical comparison group (term
births), increasing the potential for bias
(Hertz-Picciotto et al. 1996; Hinckley 2003;
Hinckley et al. 2002). Therefore, for preterm
and very preterm births, we evaluated expo-
sure to DBPs only for the specific gestation
week intervals mentioned above.
We abstracted information on potential
confounders from birth records. These vari-
ables included maternal age, race, ethnicity,
education, parity, smoking, and the Kessner
index (a measure of prenatal care adequacy)
(Kotelchuck 1994). By comparing the out-
comes over different exposure time windows
within a single community, we attempted to
control for potential residual confounders
that could not be evaluated individually.
We calculated tertiles of DBP concentra-
tions using the species-specific data from all
three water treatment regions in analyses for
potential associations with each birth outcome.
We used stratified chi-square and logistic
regression analyses to evaluate the associations
among demographic variables, exposure vari-
ables, and adverse birth outcomes. In addition,
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Table 1. Distribution of births/fetal deaths and
TTHM and HAA5 concentrations [mean (range)] by
year for the Arizona study community.
No. of births/ TTHM HAA5
fetal concentrations concentrations
Year deaths (µg/L) (µg/L)
1998 9,117 56.9 (30.1–80.8) 31.8 (9.8–48.9)a
1999 9,571 45.8 (15.7–71.3) 20.6 (13.9–25.2)a
2000 9,976 48.9 (27.8–65.9) 17.0 (7.5–25.7)
2001 10,149 46.1 (16.6–68.0) 14.4 (4.2–22.3)a
2002 9,306 43.4 (7.8–70.3) 13.7 (3.1–23.0)
aBased on data from one facility.
Table 2. Characteristics of subjects and frequency of intrauterine growth retardation, term low birth
weight, and preterm births [n (%)].
Study population Intrauterine growth Term low Very
Characteristic (% of total) retardationa birth weight preterm birth Preterm birth
Total births (% of total) 48,119 (100) 4,346 (9.5) 1,010 (2.1) 564 (1.2) 4,008 (8.3)
Maternal age (years)
< 20 5,609 (11.7) 671 (15.4) 150 (14.9) 100 (17.7) 527 (13.1)
20–29 28,366 (59.0) 2,536 (58.4) 573 (56.7) 299 (53.0) 2,190 (54.6)
≥ 30 14,076 (29.3) 1,135 (26.1) 285 (28.2) 164 (29.1) 1,281 (32.0)
Unknown 68 (0.1) 4 (0.1) 2 (0.2) 1 (0.2) 10 (0.3)
Maternal race
Caucasian 43,026 (89.4) 4,085 (94.0) 844 (83.6) 493 (87.4) 3,490 (87.1)
African American 1,347 (2.8) 114 (2.6) 52 (5.1) 41 (7.3) 173 (4.3)
Native American 1,715 (3.6) 147 (3.4) 33 (3.3) 7 (1.2) 146 (3.6)
Other 1,701 (3.5) — 64 (6.3) 14 (2.5) 151 (3.8)
Unknown 330 (0.7) — 17 (1.7) 9 (1.6) 48 (1.2)
Maternal ethnicity
Non-Hispanic 30,803 (64.0) 2,741 (63.1) 623 (61.7) 349 (61.9) 2,575 (64.2)
Hispanic 15,140 (31.5) 1,453 (33.4) 340 (33.7) 191 (33.9) 1,228 (30.6)
Unknown 2,176 (4.5) 152 (3.5) 47 (4.7) 24 (4.2) 205 (5.1)
Maternal education
≥ 1 year of college 22,435 (46.6) 1,769 (40.7) 391 (38.7) 217 (38.5) 1,779 (44.4)
High school graduate 13,427 (27.9) 1,266 (29.1) 281 (27.8) 171 (30.3) 1,139 (28.4)
< 12th grade 11,172 (23.2) 1,220 (28.1) 293 (29.0) 153 (27.1) 970 (24.2)
Unknown 1,085 (2.3) 91 (2.1) 45 (4.5) 23 (4.1) 120 (2.99)
Parity
0 18,886 (39.3) 2,023 (46.5) 440 (43.6) 249 (44.1) 1,560 (39.9)
1 14,341 (29.8) 1,180 (27.2) 291 (28.8) 165 (29.3) 1,121 (28.0)
2 8,348 (17.4) 653 (15.0) 158 (15.6) 70 (12.4) 682 (17.0)
3 3,728 (7.8) 282 (6.5) 67 (6.6) 40 (7.1) 342 (8.5)
≥ 4 2,724 (5.7) 198 (4.6) 53 (5.2) 37 (6.5) 285 (7.1)
Unknown 92 (0.2) 10 (0.2) 1 (0.0) 3 (0.5) 18 (0.5)
Prenatal care (Kessner index)
Adequate 36,271 (75.4) 3,059 (70.4) 663 (65.6) 350 (62.1) 2,604 (65.0)
Intermediate 9,117 (19.0) 941 (21.7) 243 (24.1) 124 (22.0) 948 (23.7)
Inadequate 2,731 (5.7) 346 (8.0) 104 (10.3) 90 (16.0) 456 (11.4)
Maternal smoking
No 44,139 (91.7) 3,741 (86.1) 856 (84.7) 484 (85.8) 3,527 (88.0)
Yes 3,409 (7.1) 540 (12.4) 136 (13.4) 71 (12.6) 417 (10.4)
Unknown 571 (1.2) 65 (1.5) 18 (1.8) 9 (1.6) 64 (1.6)
Maternal alcohol
No 47,176 (98.0) 4,233 (97.4) 976 (96.6) 547 (97.0) 3,906 (97.5)
Yes 291 (0.6) 39 (0.9) 11 (1.1) 5 (0.9) 29 (0.7)
Unknown 652 (1.4) 74 (1.7) 23 (2.3) 12 (2.1) 73 (1.8)
aDoes not include births at < 23 weeks’ gestation for Caucasians, African Americans, and Hispanics or births at less than
29 weeks’ gestation for Native Americans. Does not include Asian or “other” births. For intrauterine growth retardation
analyses, total number of births in data set = 41,682.all covariates significantly associated with
growth outcomes at the < 0.20 level in univari-
ate analyses were retained for inclusion in
multivariable analyses. After adjustment for
potential confounders, we calculated odds ratios
(ORs) and 95% conﬁdence intervals (CIs) for
the relationships between all individual THM
species and growth and preterm birth out-
comes. For gestation week and third-trimester
analyses, a multivariate logistic regression model
containing all individual HAAs as continuous
variables was used to evaluate the possible rela-
tionship between individual HAAs in increas-
ing the risk of growth-related outcomes. A
similar model was not created for individual
THMs because there was no evidence of any
associations with growth-related outcomes.
Results
Table 2 summarizes characteristics of subjects
and frequency of intrauterine growth retarda-
tion, term low birth weight, and preterm and
very preterm births. Most mothers were white,
non-Hispanic, nulliparous women with some
college education. Most mothers received ade-
quate prenatal care, and < 10% smoked during
pregnancy. Subjects were excluded if there was
no date for last menstrual period or no esti-
mated date of conception. The estimated date
of conception was used to estimate the last
menstrual period when data on last menstrual
period were missing or considered extreme
(> 44 weeks before the birth date). The results
were not different when using last menstrual
period, estimated date of conception, or a
combination of both methods; therefore, we
used the combined method to minimize the
number of subjects lost for this reason (n = 42).
The ORs and 95% CIs for intrauterine
growth retardation and term low birth weight
and exposure to DBPs during the third
trimester are shown in Table 3. We found no
evidence of an association with either out-
come for exposure to TTHMs or specific
brominated and chlorinated THMs. We also
found no association between exposure to
HAA5 and intrauterine growth retardation.
The second and third tertiles of exposure to
HAA5 showed evidence of a weak association
with term low birth weight [OR = 1.26 (95%
CI, 0.96–1.65), and OR = 1.25 (95% CI,
0.96–1.64), respectively] compared with ref-
erent exposure levels.
Exposures to the highest tertiles of DCAA
and TCAA were associated with an increased
risk of intrauterine growth retardation [OR =
1.28 (95% CI, 1.08–1.51), and OR = 1.19
(95% CI, 1.01–1.41), respectively]. DCAA
and TCAA were also associated with intrauter-
ine growth retardation when analyzed as con-
tinuous variables. Weak associations were
found for exposure to the highest tertile of
DBAA and DBAA analyzed as a continuous
variable, although the 95% CIs for those
results all included 1.0. Analyses of intrauter-
ine growth retardation were adjusted for par-
ity, smoking, maternal education, and Kessner
index.
The risk of term low birth weight was
increased (OR = 1.49; 95% CI, 1.09–2.04)
among women exposed to average DBAA
concentrations of ≥ 5 µg/L during the third
trimester compared with those who were
exposed to the referent category of < 4 µg/L.
Continuous (unit) increases in average expo-
sure to DBAA also indicated a weak associa-
tion with term low birth weight (OR = 1.17;
95% CI 1.03–1.32). Analyses of term low
birth weight were adjusted for maternal age,
parity, education, race, ethnicity, smoking,
and Kessner index.
Table 4 presents ORs and 95% CIs for
exposure to HAA5 and individual HAAs over
speciﬁc gestation time windows for intrauterine
growth retardation and term low birth weight.
Because the potential for bias due to averaging
was reduced when examining shorter time
intervals, exposure values were generally
slightly higher or slightly lower over the spe-
cific gestation week intervals than over the
third trimester. In analyses for intrauterine
growth retardation, small increases in risk were
observed for DBAA concentrations ≥ 5 µg/L
(OR = 1.15; 95% CI, 0.98–1.35) and for
DBAA analyzed as a continuous variable
(OR = 1.06; 95% CI, 1.01–1.12) over gesta-
tion weeks 25–28. The largest risk was
observed with exposure to DCAA ≥ 8 µg/L
(OR = 1.27; 95% CI, 1.02–1.59) during ges-
tation weeks 37–40. In addition, an increased
risk was observed for exposure to moderate
concentrations of TCAA (OR = 1.58; 95%
CI, 1.02–2.46) and DCAA (OR = 1.51; 95%
CI, 0.98–2.32) during gestation weeks 41–44,
but the risk estimates were lower at higher
levels of estimated exposure.
Exposure to DBAA was associated with
an increase in risk for term low birth weight
Hinckley et al.
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Table 3. ORs and 95% CIs for the association between exposure to DBPs averaged over the entire third
trimester and intrauterine growth retardation and term low birth weight.
Intrauterine growth retardationa Term low birth weightb
DBP (µg/L) Cases (n) OR (95% CI) Cases (n) OR (95% CI)
TTHMs (n)c 39,954 38,096
< 40 1,208 — 269 —
40–53 1,198 0.98 (0.90–1.07) 284 1.06 (0.89–1.25)
≥ 53 1,354 1.09 (1.00–1.18) 306 1.11 (0.94–1.31)
Continuous 3,760 1.00 (1.00–1.01) 859 1.00 (1.00–1.01)
Chloroform
< 10 1,216 — 265 —
10–16 1,258 1.02 (0.94–1.11) 312 1.18 (1.00–1.39)
≥ 16 1,286 1.01 (0.93–1.10) 282 1.04 (0.88–1.23)
Continuous 3,760 1.00 (1.00–1.01) 859 1.00 (1.00–1.01)
BDCM
< 13 1,251 — 274 —
13–18 1,173 0.93 (0.85–1.01) 290 1.05 (0.89–1.24)
≥ 18 1,336 1.03 (0.95–1.12) 295 1.04 (0.88–1.23)
Continuous 3,760 1.00 (1.00–1.01) 859 1.00 (0.99–1.02)
DBCM
< 12 1,288 — 286 —
12–16 1,164 0.96 (0.89–1.05) 269 1.00 (0.84–1.18)
≥ 16 1,308 1.01 (0.94–1.10) 304 1.05 (0.89–1.24)
Continuous 3,760 1.01 (1.00–1.01) 859 1.01 (0.99–1.02)
HAA5 (n) 14,350 13,981
< 15 462 — 97 —
15–19 466 1.00 (0.87–1.15) 124 1.26 (0.96–1.65)
≥ 19 513 1.08 (0.94–1.23) 126 1.25 (0.96–1.64)
Continuous 1,441 1.0 (1.00–1.01) 347 1.01 (1.00–1.02)
DBAA (n)d 9,576 9,312
< 4 322 — 70 —
4–5 301 1.04 (0.88–1.23) 71 1.01 (0.72–1.41)
≥ 5 347 1.12 (0.95–1.32) 103 1.49 (1.09–2.04)
Continuous 970 1.05 (0.98–1.12) 244 1.17 (1.03–1.32)
DCAA
< 6 268 — 76 —
6–8 332 1.15 (0.97–1.36) 81 1.04 (0.75–1.43)
≥ 8 370 1.28 (1.08–1.51) 87 1.10 (0.80–1.50)
Continuous 970 1.05 (1.02–1.09) 244 1.02 (0.96–1.08)
TCAA
< 4 277 — 73 —
4–6 309 1.00 (0.84–1.18) 81 0.94 (0.68–1.30)
≥ 6 384 1.19 (1.01–1.41) 90 1.00 (0.73–1.37)
Continuous 970 1.04 (1.02–1.07) 244 1.01 (0.96–1.05)
aAdjusted for parity, education, smoking, and Kessner index. bAdjusted for maternal age, parity, education, race, ethnicity,
smoking, and Kessner index. cSample sizes used in analysis of chloroform, BDCM, and DBCM were equal for third-trimester
analyses. dSample sizes used in analysis of DBAA, DCAA, and TCAA were equal for third-trimester analyses.in analyses by gestation week. Between gesta-
tion weeks 33 and 36, the second and third
tertiles of exposure to DBAA showed evi-
dence of a dose-dependent trend [OR = 1.29
(95% CI, 0.94–1.79), and OR = 1.49 (95%
CI, 1.10–2.02), respectively] compared with
referent exposure levels. Similarly, moderate
exposure to DBAA between gestation weeks
37 and 40 was associated with an increased
risk for term low birth weight (OR = 1.38;
95% CI, 1.02–1.86).
No associations were observed between
preterm or very preterm birth and exposure to
TTHMs, HAA5, or speciﬁc DBPs during any
gestation week interval. ORs for the associa-
tions between individual HAAs and term low
birth weight and intrauterine growth retarda-
tion were not affected by inclusion of other
HAAs in the logistic regression model.
Discussion
Reduced fetal weight is one of the most
consistent developmental effects observed
with exposure to high concentrations of
DBPs in laboratory animals (Nieuwenhuijsen
et al. 2000). The biologic mechanisms for
DBP-induced growth retardation are not well
understood. In animal studies, reductions in
birth weight have been commonly described
after exposure to THMs, especially chloro-
form (Murray et al. 1979; Ruddick et al.
1983; Schwetz et al. 1974; Thompson et al.
1974). Two studies by Smith et al. (1989,
1992) found reductions in rat pup body
weight after exposure to DCAA and TCAA.
Recently, Christian et al. (2001) found that
DBAA administration (of 250, 500, and
1,000 mg/L) was associated with exposure-
related decreases in rat pup body weight. This
effect, however, was thought to be due to
reduced parental water consumption.
The epidemiologic evidence for an associa-
tion between exposure to THMs and indica-
tors of fetal growth is relatively sparse and
inconsistent, and few studies have investigated
this relationship with respect to HAAs. Four
prior epidemiologic studies have evaluated
exposure to total and individual THMs in
relation to intrauterine growth retardation. In
a study by Kramer et al. (1992), a dose-related
trend was observed for intrauterine growth
retardation at the 5th percentile for exposure
to chloroform ≥ 10 µg/L and BDCM
≥ 4 µg/L, with ORs of 1.8 (95% CI, 1.1–2.9)
and 1.7 (95% CI, 0.9–2.9), respectively. Bove
et al. (1995) also found an increased risk of
intrauterine growth retardation (adjusted
OR = 1.50; 90% CI, 1.19–1.86) with expo-
sure to TTHMs > 100 µg/L during preg-
nancy. In a Massachusetts cohort, Wright
et al. (2003) found increased risk of intra-
uterine growth retardation (10th percentile)
for mean exposures to TTHMs > 80 µg/L
throughout pregnancy (adjusted OR = 1.14;
95% CI, 1.02–1.26) and during the second
trimester (adjusted OR = 1.13; 95% CI,
1.03–1.24). However, Dodds et al. (1999)
found no association between intrauterine
growth retardation (10th percentile) and
TTHM exposure ≥ 100 µg/L in a large cohort
of Nova Scotia women.
Three studies have evaluated term low
birth weight and exposure to TTHMs.
Gallagher et al. (1998) found an adjusted OR
of 5.9 (95% CI, 2.0–17.0) for term births,
although only six cases were analyzed. Bove
et al. (1995) also observed a positive, but
smaller, association between TTHM exposures
averaged over the entire pregnancy and term
low birth weight with an OR of 1.42 (50% CI,
1.22–1.65). In a study by Wright et al. (2003),
no associations were reported between term
low birth weight and trimester-speciﬁc expo-
sures or entire pregnancy exposures to
TTHMs. Six studies have evaluated preterm
birth or very preterm birth; none found a sig-
nificant relationship with DBPs (Bove et al.
1995; Dodds et al. 1999; Gallagher et al. 1998;
Kramer et al. 1992; Savitz et al. 1995; Wright
et al. 2003).
As a group, these studies differed in their
selection of a referent group for exposure, in
their ability to control for potential confound-
ing, and in their assessment of exposure during
the third trimester or late stages of pregnancy.
To evaluate the relationship between TTHMs
and growth-related birth outcomes, Bove et al.
(1995) averaged quarterly TTHM concen-
trations over each subject’s entire pregnancy.
In a study of miscarriage, low birth weight
and preterm delivery in North Carolina, Savitz
et al. (1995) assigned exposure by using the
quarterly value nearest the 28th week of preg-
nancy. Gallagher et al. (1998) used the median
of all quarterly measurements taken during
the third trimester. For children born in the
Late pregnancy exposures to DBPs
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Table 4. ORs (95% CIs) for term low birth weight and intrauterine growth retardation by gestation week (GW)
according to level of DBP exposure.
DBP (µg/L) GW 25–28 GW 29–32 GW 33–36 GW 37–40 GW 41–44
Intrauterine growth retardationa
HAA5 (n) 14,350 14,953 15,414 14,929 2,634
< 14 —
14–19 1.02 (0.89–1.17) 1.00 (0.86–1.13) 0.93 (0.81–1.06) 0.99 (0.86–1.13) 1.22 (0.86–1.72)
≥ 19 1.12 (0.98–1.29) 1.11 (0.98–1.27) 1.00 (0.88–1.14) 0.98 (0.85–1.13) 0.91 (0.63–1.33)
Continuous 1.01 (1.00–1.01) 1.01 (1.00–1.01) 1.00 (0.99–1.01) 1.00 (0.99–1.01) 1.00 (0.98–1.01)
DBAA (n)b 9,576 10,302 10,945 10,875 1,913
< 3 —
3.5–5 1.00 (0.84–1.18) 0.97 (0.82–1.14) 1.14 (0.97–1.34) 0.95 (0.81–1.12) 1.23 (0.82–1.85)
≥ 5 1.15 (0.98–1.35) 1.06 (0.91–1.24) 1.08 (0.93–1.27) 0.90 (0.77–1.06) 0.91 (0.60–1.40)
Continuous 1.06 (1.01–1.12) 1.03 (0.99–1.08) 1.01 (0.96–1.06) 0.99 (0.94–1.04) 0.97 (0.85–1.10)
DCAA
< 6 —
6–8 1.00 (0.85–1.18) 1.06 (0.90–1.25) 0.92 (0.78–1.08) 1.00 (0.85–1.18) 1.51 (0.98–2.32)
≥ 8 1.04 (0.85–1.29) 1.11 (0.90–1.35) 1.03 (0.84–1.26) 1.27 (1.02–1.59) 1.41 (0.85–2.33)
Continuous 1.02 (0.99–1.04) 1.03 (1.01–1.05) 1.03 (1.01–1.05) 1.03 (1.01–1.05) 1.03 (0.98–1.08)
TCAA
< 4 —
4–6 0.96 (0.81–1.14) 1.05 (0.89–1.24) 0.91 (0.78–1.07) 1.12 (0.95–1.32) 1.58 (1.02–2.46)
≥ 6 1.01 (0.86–1.19) 1.15 (0.98–1.34) 1.07 (0.92–1.24) 1.15 (0.98–1.35) 1.48 (0.96–2.31)
Continuous 1.01 (1.00–1.03) 1.02 (1.01–1.04) 1.03 (1.01–1.05) 1.02 (1.01–1.04) 1.02 (0.98–1.06)
Term low birth weightc
HAA5 (n) 13,981 14,593 15,195 15,780 2,755
< 14 —
14–19 0.91 (0.69–1.18) 1.04 (0.79–1.36) 1.04 (0.80–1.36) 1.12 (0.87–1.44) 0.74 (0.28–1.98)
≥ 19 1.05 (0.81–1.36) 1.30 (1.00–1.69) 1.20 (0.93–1.55) 1.08 (0.83–1.40) 1.03 (0.39–2.72)
Continuous 1.01 (0.99–1.02) 1.01 (1.00–1.02) 1.00 (1.01–1.02) 1.00 (0.99–1.02) 0.99 (0.95–1.04)
DBAA (n)b 9,312 10,043 10,778 11,484 2,003
< 3 —
3.5–5 0.97 (0.69–1.35) 1.05 (0.77–1.45) 1.29 (0.94–1.79) 1.38 (1.02–1.86) 0.99 (0.34–2.85)
≥ 5 1.16 (0.86–1.58) 1.18 (0.87–1.61) 1.49 (1.10–2.02) 1.22 (0.90–1.66) 0.38 (0.10–1.43)
Continuous 1.03 (0.94–1.12) 1.07 (0.98–1.17) 1.11 (1.01–1.21) 1.10 (1.01–1.20) 0.88 (0.62–1.23)
DCAA
< 6 — —
6–8 0.80 (0.58–1.09) 0.84 (0.61–1.15) 0.94 (0.69–1.27) 0.98 (0.74–1.32) 0.45 (0.13–1.60)
≥ 8 0.87 (0.64–1.18) 0.99 (0.74–1.32) 0.98 (0.73–1.30) 0.91 (0.68–1.21) 0.93 (0.33–2.57)
Continuous 1.01 (0.97–1.05) 1.02 (0.98–1.06) 1.00 (0.96–1.04) 1.01 (0.97–1.05) 0.94 (0.81–1.09)
TCAA
< 4 —
4–6 0.79 (0.57–1.09) 0.91 (0.67–1.24) 1.05 (0.77–1.42) 1.15 (0.86–1.53) 0.40 (0.11–1.30)
≥ 6 0.89 (0.66–1.20) 0.98 (0.73–1.33) 1.05 (0.78–1.41) 0.93 (0.69–1.25) 0.64 (0.23–1.79)
Continuous 1.01 (0.98–1.05) 1.01 (0.98–1.04) 1.00 (0.96–1.03) 1.00 (0.96–1.03) 0.93 (0.80–1.09)
aAdjusted for parity, education, smoking, and Kessner index. bSample sizes used in analysis of DBAA, DCAA, and TCAA were
equal for each gestation age interval. cAdjusted for maternal age, parity, education, race, ethnicity, smoking, and Kessner index.second or third month of the quarter, Wright
et al. (2003) used the average quarterly values
for the third trimester; children born in the
first month of the quarter were assigned the
preceding quarterly averages. In Nova Scotia,
Dodds et al. (1999) used linear regression of
quarterly data to estimate average exposures
during the last 3 months of pregnancy. Our
method of assigning exposure included esti-
mating some periodic study time exposures
using a spline regression based on quarterly
sampling values. Further, all data were inter-
polated from month midpoint and converted
to ordinal study time, to better align with ges-
tation time (Yang et al. 2005). This regression
method, which is similar to that used in the
Nova Scotia studies, permitted estimation of
exposure for time periods when data were
missing or when sampling was not performed.
We performed a sensitivity analysis by sys-
tematically repeating the spline regression
with varying subsets of exposure data. By this
method, we found that the model consis-
tently predicted existing data points to within
± 5%. However, the spline regression tech-
nique requires additional validation in other
distribution systems.
Our study is the ﬁrst to examine associa-
tions between exposures to speciﬁc HAAs and
impaired fetal growth. We found evidence of
associations between exposure to specific
HAAs and term low birth weight and intra-
uterine growth retardation. The second and
third tertiles of exposure to HAA5 were also
associated with a small increase in risk for term
low birth weight when evaluated over the
third trimester (Table 3). The increased risk in
the second tertile did not seem to be due to a
higher risk from DBAA, DCAA, or TCAA.
HAA5 concentration is currently regulated in
the United States, but concentrations of spe-
cific HAAs are not. Our findings suggest a
critical window of exposure during weeks
33–40 for the effects of DBAA on fetal devel-
opment. To our knowledge, this is the first
time that DBAA has been investigated in an
epidemiologic study of developmental out-
comes. Studies of exposure to HAAs are rela-
tively new, and none have been performed in
communities where DBAA concentrations in
drinking water were above detection (King
et al. 2005; Wright et al. 2004). In this inves-
tigation, the levels of DBAA were well above
the 90th percentile concentrations reported by
the U.S. EPA (1998).
We also observed evidence of an associa-
tion between intrauterine growth retardation
and exposure to chlorinated HAAs during spe-
ciﬁc critical time windows of gestation, with
modest increases in risk for third-trimester
exposure to DCAA and slightly lower estimates
for TCAA. When analyzed as continuous
variables, exposure to DCAA and TCAA also
showed slight increases in risk of intrauterine
growth retardation between weeks 29 and 40
of gestation. The risk estimates remained con-
sistent during the gestation week windows
comprising this time period.
Our study is the ﬁrst to examine exposure
to DBPs during speciﬁc gestation week inter-
vals of exposure. In previous studies, exposure
for fetal development was usually averaged over
the longer third-trimester window. Averaging a
variable exposure over longer time periods such
as the third trimester is likely to introduce mis-
classiﬁcation over the critical time periods and
lead to biased risk estimates (Hertz-Picciotto
et al. 1996). However, for the highest level of
exposure to DBAA, we observed the same OR
for exposure averaged over the third trimester
as for exposure averaged over gestation weeks
33–36. The CIs were narrower for DBAA
exposure during weeks 33–36 than for the
entire third trimester, reﬂecting increased pre-
cision due to the slightly larger sample popula-
tion retained for analysis of gestation week
intervals. Because the third trimester is a longer
time period, it is more likely to fall outside of
the study initiation and termination (or begin-
ning and end) date than are single week-long
periods (Hinckley 2003; Hinckley et al. 2002).
Windows of exposure have been histori-
cally important in epidemiologic investiga-
tions of thalidomide, retinoic acid (vitamin
A), maternal rubella, and radiation (O’Rahilly
and Muller 2001). For exposures during the
first 2 weeks of gestation, few congenital
abnormalities are observed because the terato-
gen either damages most cells, resulting in cell
and embryonic death, or affects only a few
cells that can be repaired without resultant
birth defects (Moore and Persaud 1998).
After the ﬁrst 2 weeks, the tissue or organ that
is most susceptible to malformation is the
part undergoing critical development when
the teratogen is active. Exposures that occur
later in gestation have a less drastic effect and
are thought to primarily affect fetal growth.
The strengths of this study include the
large number of birth records, high quantity
of exposure data (including some biweekly
data), and the ability to evaluate multiple
time periods of exposure to specific THMs
and HAAs. By comparing subjects within the
same community with respect to exposure
levels, we may have reduced potential residual
confounding. We also selected this commu-
nity to minimize misclassiﬁcation due to spa-
tial variability within the distribution systems
(Hinckley et al. 2005).
Our study was limited by the use of birth
records to ascertain individual exposure infor-
mation. Maternal residence was identified
from birth records to assign the appropriate
water service, but residential mobility during
pregnancy may have introduced exposure mis-
classiﬁcation. Potential exposure misclassiﬁca-
tion could also have resulted from lack of
information regarding exposures from inhala-
tion or dermal exposure from showering,
bathing, and washing. Exposure estimates
were based on distribution system DBP con-
centrations and did not account for variability
in personal habits affecting ingestion, such as
the use of bottled water (Zender et al. 2001).
Finally, exposure misclassiﬁcation could have
resulted from exposures outside the service
area (e.g., at work) of the designated water
treatment system.
In summary, despite toxicologic evidence of
growth retardation after exposure to DBPs, few
human studies have been conducted on this
relationship. The pervasive nature of the expo-
sure suggests that even small effects may be
important. This work explored this relationship
using seasonal variability and intracommunity
comparisons to define a natural experiment.
We improved on previous exposure assessments
by considering total and individual THMs and
HAAs, and multiple time periods of exposure
in late gestation. Further studies are needed
to conﬁrm our observations for DBAA, TCAA,
and DCAA as well as other relationships
between DBPs and growth outcomes.
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